MX2009013202A - Derivados terapeuticos de pirazoloquinolina. - Google Patents

Derivados terapeuticos de pirazoloquinolina.

Info

Publication number
MX2009013202A
MX2009013202A MX2009013202A MX2009013202A MX2009013202A MX 2009013202 A MX2009013202 A MX 2009013202A MX 2009013202 A MX2009013202 A MX 2009013202A MX 2009013202 A MX2009013202 A MX 2009013202A MX 2009013202 A MX2009013202 A MX 2009013202A
Authority
MX
Mexico
Prior art keywords
gabaa
formula
animal
compound
pyrazoloquinoline derivatives
Prior art date
Application number
MX2009013202A
Other languages
English (en)
Inventor
Alan P Kaplan
Varsha Gupta
Jan W F Wasley
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of MX2009013202A publication Critical patent/MX2009013202A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invenci?n proporciona una nueva serie qu?mica de la f?rmula (I), as? como m?todos para su uso para enlazarse al sitio de benzodiazepina del receptor GABAA y modular GABAA, y al uso del compuesto de la f?rmula (I) en la elaboraci?n de un medicamento para el tratamiento de trastornos asociados al receptor GABAA. La invenci?n proporciona adem?s un m?todo para la modulaci?n de uno o m?s subtipos de GABAA en un animal, que comprende administrar al animal una cantidad efectiva de un compuesto de la f?rmula (I).
MX2009013202A 2007-06-08 2008-06-06 Derivados terapeuticos de pirazoloquinolina. MX2009013202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94300507P 2007-06-08 2007-06-08
PCT/US2008/066201 WO2008154438A1 (en) 2007-06-08 2008-06-06 Therapeutic pyrazoloquinoline derivatives

Publications (1)

Publication Number Publication Date
MX2009013202A true MX2009013202A (es) 2010-04-09

Family

ID=40096440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013202A MX2009013202A (es) 2007-06-08 2008-06-06 Derivados terapeuticos de pirazoloquinolina.

Country Status (14)

Country Link
US (2) US7872002B2 (es)
EP (1) EP2166852B1 (es)
JP (1) JP2010529143A (es)
KR (1) KR20100039331A (es)
CN (1) CN101742908A (es)
AT (1) ATE544344T1 (es)
AU (1) AU2008261884A1 (es)
BR (1) BRPI0812366A2 (es)
CA (1) CA2688395A1 (es)
ES (1) ES2386168T3 (es)
HK (1) HK1142775A1 (es)
IL (1) IL202270A0 (es)
MX (1) MX2009013202A (es)
WO (1) WO2008154438A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101686682A (zh) * 2007-06-08 2010-03-31 海利空医疗公司 治疗用吡唑并喹啉脲衍生物
MX2009013197A (es) * 2007-06-08 2010-04-27 Helicon Therapeutics Inc Derivados terapeuticos de pirazolonaftiridina.
CN101742908A (zh) * 2007-06-08 2010-06-16 海利空医疗公司 治疗用吡唑并喹啉衍生物
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CN108431000A (zh) * 2015-11-16 2018-08-21 基础应用医学研究基金会 作为dna甲基转移酶抑制剂的新型化合物
CN105294648B (zh) * 2015-11-30 2017-11-28 山东罗欣药业集团股份有限公司 一种西他沙星的制备方法
WO2022037631A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3204126A1 (de) 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4814450A (en) 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
JPS61112075A (ja) * 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
EP0214092A1 (en) 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5334595A (en) * 1992-10-23 1994-08-02 Sterling Winthrop Inc. Pyrazoloquinolones as anticancer agents
GB9716347D0 (en) 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
JP3896309B2 (ja) * 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
ATE425164T1 (de) 2002-12-16 2009-03-15 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
TW200508233A (en) 2003-05-29 2005-03-01 Millennium Pharm Inc Chk-1 inhibitors
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2621560A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
JP2008047893A (ja) * 2006-08-11 2008-02-28 Samsung Electronics Co Ltd 薄膜トランジスタ表示板及びその製造方法
CN101742908A (zh) * 2007-06-08 2010-06-16 海利空医疗公司 治疗用吡唑并喹啉衍生物

Also Published As

Publication number Publication date
US7872002B2 (en) 2011-01-18
US20110065693A1 (en) 2011-03-17
IL202270A0 (en) 2010-06-16
JP2010529143A (ja) 2010-08-26
EP2166852A1 (en) 2010-03-31
CN101742908A (zh) 2010-06-16
AU2008261884A1 (en) 2008-12-18
HK1142775A1 (en) 2010-12-17
EP2166852A4 (en) 2010-07-07
ATE544344T1 (de) 2012-02-15
WO2008154438A1 (en) 2008-12-18
CA2688395A1 (en) 2008-12-18
US20080306049A1 (en) 2008-12-11
BRPI0812366A2 (pt) 2016-08-02
KR20100039331A (ko) 2010-04-15
ES2386168T3 (es) 2012-08-10
EP2166852B1 (en) 2012-02-08
US8598159B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
MX2009013205A (es) Derivados de pirazoloquinolina urea terapeuticos.
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
MX2009013202A (es) Derivados terapeuticos de pirazoloquinolina.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
MX2009011878A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina.
ATE432279T1 (de) Tricyclische delta-opioid-modulatoren
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
DK1730147T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
TW200621767A (en) Tricyclic δ-opioid modulators
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
UA104880C2 (uk) Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях
TW200606148A (en) Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten

Legal Events

Date Code Title Description
FG Grant or registration